Dr. Paul Keim's research in pathogen genomics and microbiology has been recognized for its importance in bolstering the nation's biodefense and preventing outbreaks of infectious diseases. His work has led to significant advancements in genomic investigations, including the detection of antibiotic resistance and antiviral resistance.
A new study by TGen, Mayo Clinic and SHC demonstrated the power of whole genome sequencing in advancing understanding of pancreatic cancer. The research identified 142 cellular genetic coding events, including mutations, insertions and deletions, in three patients with pancreatic adenocarcinoma.
TGen's Dr. Daniel Von Hoff delivers his lecture on a molecular pursuit approach to take out pancreatic cancer, honoring the memory of patient Lori Groetken who fought the disease for two years. The award recognizes his significant contributions to genomic research and novel therapy development in pancreatic cancer.
Researchers tracked tumor evolution in a patient with maxillary sinus carcinoma, identifying genetic changes that contribute to drug resistance. The study provides a roadmap for treating this rare and aggressive cancer.
A Phase I/II trial tests the safety and efficacy of PR610 in patients with advanced cancer. The study aims to deliver a targeted approach, activating the compound in tissues with low oxygen levels characteristic of many cancers.
Lynn and Foster Friess are donating up to $100,000 to support ovarian cancer research at the Translational Genomics Research Institute. The challenge aims to advance cutting-edge genetic technology in pursuit of better cancer treatments.
TGen researchers will identify genetic differences in glioblastoma patients using whole genome sequencing, with the goal of developing personalized clinical trials. The foundation's funding supports two five-year projects aimed at extending patient survival and improving treatment outcomes.
Researchers at TGen developed a method to isolate protein-rich urinary exosomes, which can help discover biomarkers for better CKD diagnosis and treatment. The study found that the new method produces high yields of miRNA and mRNA, making it suitable for downstream genetic profiling experiments.
A Phase 2 clinical trial is underway to test the effectiveness and safety of INNO-206 in treating advanced pancreatic ductual adenocarcinomas. The drug works like a Trojan Horse by being prepared in albumin, which pancreatic cancer cells prefer, allowing it to deliver cancer-killing agents directly to the tumor.
The new skin cancer drug vismodegib was approved by the FDA in 2012 for treating locally advanced and metastatic basal cell carcinomas. It blocks the Hedgehog signaling pathway and has shown promising results for patients with inherited genetic susceptibility.
A study conducted by TGen-Scottsdale Healthcare analyzed the patient's tumor and normal DNA to identify significant gene mutations that could be targeted for therapy. The analysis provided clues to possible precision medicine treatment of rare nasal tract cancer.
Saks Fifth Avenue's month-long charity drive raised $1.1 million for 196 organizations, including $17,000 for TGen biomedical research. The program linked customer accounts with chosen charities, allowing for significant charitable contributions.
The new Bio4D software program will manage biological repositories for genetic and genomic research, including blood, DNA, and tissue samples. It aims to accelerate discovery in the laboratory and help translate information to oncologists working with clinical patients.
A $4.5 million grant will fund the search to find new ways of treating glioblastoma multiforme (GBM), the most common type of primary brain tumors. The study aims to discover new medicines that can precisely target tumors, shrinking or eliminating them with minimal harm.
The Ben & Catherine Ivy Foundation funds a $45,000 pilot internship program at TGen to provide hands-on biomedical research experience for high school and undergraduate students. The program aims to inspire future leaders in the field of neuroscience and brain tumor research.
A first-of-its-kind clinical trial demonstrated the feasibility of selecting treatment based on individual molecular characteristics in advanced pancreatic cancer. The study found that biopsies could be safely conducted and multiple drug targets identified, suggesting potential benefits for some patients.
The MMRF has partnered with TGen, Spectrum Health, and VARI to provide genomic services and analyze patient samples in a landmark 1000-patient study on multiple myeloma. The study aims to identify specific subgroups of patients and provide insights into the molecular changes that affect disease progression.
A clinical trial involving 14 TNBC tumors explores the use of whole-genome sequencing to identify potential treatment options. The study aims to advance personalized medicine and guide treatment for individual patients.
Researchers found 22% of TNBC patients had the androgen receptor, which was linked to more aggressive cancer but not necessarily worse survival rates. The study suggests targeting the androgen receptor could be a new way to treat TNBC.
Scientists at Fred Hutchinson Cancer Research Center and TGen have discovered a way to break down the biological barrier surrounding pancreatic cancer tumors, allowing chemotherapy drugs to reach the cancerous tissue. This breakthrough could lead to improved survival rates for patients with pancreatic cancer.
The 9th annual Seena Magowitz Celebrity Golf Classic raised funds for pancreatic cancer research at the Translational Genomics Research Institute (TGen). The event supported new international clinical trials and initiatives against pancreatic cancer.
A recent study led by TGen found that a strain of methicillin-resistant Staphylococcus aureus (MRSA) originated in humans before spreading to food animals and becoming resistant to antibiotics. The study used whole genome sequencing to trace the history of MRSA CC398, a strain often referred to as 'pig-MRSA'.
A recent study found that the STAT3 gene is activated in some non-small cell lung cancer cell lines by the JAK2 protein, which may not be effectively inhibited by drugs targeting specific mutations. This suggests a potential role for combination therapy to combat NSCLC driven by STAT3-JAK2 signaling.
A global conversation is needed to address the risks of avian flu research, according to a new policy statement. The National Science Advisory Board for Biosecurity warns that publishing certain research details could lead to the development of deadly transmissible influenza viruses.
Researchers at the Translational Genomics Research Institute and University of Arizona have received a grant to study targeted cancer therapies for pancreatic cancer, which shows promise in reducing side effects. The center aims to develop novel antitumor agents that can extend the productive lives of patients with cancer.
A 1993 Chevrolet Corvette 40th Anniversary coupe was sold at the Barrett-Jackson Scottsdale Auction, raising $120,000 for cancer research at TGen. The funds support research into colon and prostate cancer in memory of Russ and Brian Jackson.
TGen researchers identify multiple novel mutations and pathway changes in never-smoker lung cancer patients, diverging from those found in smokers. These findings hold promise for developing therapeutic targets in this patient population.
Whole-genome sequencing reveals activation of targets for new treatment strategies, including MEK/AKT inhibitors for metastatic triple negative breast cancers. The study's results indicate potential for improved treatment options for nearly 20% of breast cancers that do not respond to targeted therapies.
The 'Seena I' clinical trial aims to find a cure for pancreatic cancer by attacking all components of the tumor. The trials are supervised by the Pancreatic Cancer Research Team and involve four clinical sites across the nation.
The study reveals co-activating events in the MAPK and PI3K/AKT pathways, leading to targeted treatments with significant patient benefits. Physicians steered patients into tailored treatment plans based on sequencing data, resulting in improved outcomes.
The Waylon Fund will support state-of-the-art investigations into the genetic and genomic origins of diabetes, aiming to produce better treatments. Donations will also enable comprehensive genomic analysis using the latest technology to accelerate research.
A new drug combination of gemcitabine and nab-paclitaxel has shown impressive results in a clinical trial for patients with advanced pancreatic cancer. The study, led by Dr. Daniel Von Hoff, found that about half the patients showed reductions in tumor size and about 50 percent lived at least a year.
Two Arizona university graduate students working at TGen have received $50,000 grants to study antibiotic resistance and Alzheimer's disease. The research will focus on understanding genetic mechanisms behind antibiotic resistance and developing models for neurodegenerative diseases.
A multi-institute team led by TGen will study triple-negative breast cancer, a highly aggressive form of the disease that disproportionately affects African-Americans. The research aims to uncover new ways of treating this aggressive form of breast cancer by understanding molecular makeup of breast cancer stem cells.
The Translational Genomics Research Institute (TGen) has been awarded $50,000 by the Inflammatory Breast Cancer Research Foundation to discover the genetic origins of Inflammatory Breast Cancer (IBC), a rare and aggressive form of breast cancer that rapidly progresses without warning.
Mattress Firm Foundation is committed to raising awareness and funding for TGen's globalCure clinical trials, focusing on funding research and clinical trials. The company has already raised over $400,000 through employee donation programs and online fundraising platforms.
The Translational Genomics Research Institute (TGen) has launched the Helios Scholars Program, a 8-week internship that strengthens biomedical education. The program provides high school, undergraduate and graduate level students with hands-on research access in state-of-the-art laboratories.
A new drug targeting the PI3K gene has shown significant shrinkage of tumors in two patients with advanced breast and cervical cancers. The drug, GDC-0941, is being tested in an early phase I study conducted by TGen and Virginia G. Piper Cancer Center.
Researchers at TGen present two key studies on the role of genes and proteins in therapeutic treatments for lung cancer. The studies suggest that combination drug therapy may be necessary to combat non-small cell lung cancer, particularly when patients have elevated levels of a protein called JAK2.
Researchers sequenced a patient's entire DNA and RNA to identify the origins of their metastatic adenocarcinoma of the lung, a mutation in the TP53 gene being found to halt tumor suppressor gene creation and result in tumor generation
Bacteria can evade the immune system by mimicking human proteins, allowing them to resist antibiotics. This 'molecular mimicry' helps explain the resurgence of highly infectious pathogens.
Researchers at TGen found that naturally occurring plant compounds could slow down Alzheimer's disease by inhibiting a protein linked to memory loss. Harmine and other beta-carboline alkaloids show promise as therapeutic drugs, targeting tau phosphorylation and neurofibrillary tangles.
Researchers at TGen found that PVT1 expression levels increased up to 5-fold in response to hyperglycemia, leading to excessive accumulation of extracellular matrix in glomeruli. Knocking down PVT1 reduced ECM protein levels, suggesting a potential molecular mechanism for diabetic nephropathy.
A group of Ohio greenhouse growers partners with the Translational Genomics Research Institute to sell 'denim shock wave petunias' in support of pancreatic cancer awareness. The program aims to raise funds for TGen's globalCure initiative, which seeks to find a cure for pancreatic cancer.
A nationwide study found nearly half of US meat and poultry samples contaminated with drug-resistant Staphylococcus aureus. The bacteria can cause serious illnesses like pneumonia, endocarditis, and sepsis, highlighting the need for a more comprehensive inspection program.
A new study finds that vismodegib, a hedgehog pathway inhibitor, prevents the development of advanced basal cell carcinomas in patients with basal cell nevus syndrome. The treatment also shows promise for patients with an inherited predisposition to basal cell carcinoma.
Mattress Firm has named Translational Genomics Research Institute as its charitable partner of choice to support globalCure's fight against pancreatic cancer. The company will donate $50 to globalCure for every Simmons Beautyrest dual floor sample sold nationwide, aiming to raise over $100,000.
PBS-Bio presents two abstracts at the AACR conference, showing how drugs UNBS1450 and NDC-1308 affect cancer cells. The technology allows real-time measurement of cellular responses to drugs, identifying potential biomarkers for patient selection and drug development.
A study published by Scottsdale Healthcare and TGen identified microRNA-328 as a biomarker that can predict lung cancer patients' risk of developing brain metastasis. The study found that over-expression of microRNA-328 resulted in increased cancer cell migration, suggesting its involvement in 'brain-seeking' metastatic potential.
Shannon Fortin, a University of Arizona graduate student at TGen, has been awarded the $7,000 Achievement Rewards for College Scientists scholarship. This award will enable her to pursue two simultaneous post-graduate degrees while continuing her research on glioblastoma multiforme, the most malignant form of brain cancer.